Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BlaIMP-15 in Pseudomonas aeruginosa in Switzerland

ABSTRACT: First case of IMP-15-producing Pseudomonas aeruginosa in Switzerland

PROVIDER: PRJEB37060 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR3973985_1.fastq.gz	Fastqsanger.gz
	ERR3973985_2.fastq.gz	Fastqsanger.gz
	ERR3973986_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

IMP-producing Pseudomonas aeruginosa

Project description:IMP-producing Pseudomonas aeruginosa

| PRJEB53622 | ENA

Pseudomonas aeruginosa

Project description:IMP-13 producing Pseudomonas aeruginosa

| PRJNA1106512 | ENA

Pseudomonas aeruginosa strain:IMP-13

Project description:Pseudomonas aeruginosa strain:IMP-13 Genome sequencing

| PRJNA507737 | ENA

Project description:IMP-63 producing Pseudomonas aeruginosa and Pseudomonas putida

| PRJNA496031 | ENA

Pseudomonas aeruginosa

Project description:Carbapenemase-producing P. aeruginosa

| PRJNA767505 | ENA

GNPS_Microcystis aeruginosa

Project description:Metabolic profiles of microcystin and non-microcystin-producing Microcystis aeruginosa strains (Cyanobacteria).

2014-07-09 | MSV000078776 | GNPS

Staphylococcus aureus population structure and genomic profiles in asymptomatic carriers in Switzerland

Project description:genomic profiles of Staphylococcus aureus isolates from asymptomatic carriers in Switzerland

2020-04-08 | E-MTAB-8960 | biostudies-arrayexpress

Project description:WGS of clinical Pseudomonas aeruginosa (IMP-producing) from Brazil

| PRJNA1101556 | ENA

Cysteamine inhibits glycine utilisation and disrupts virulence in Pseudomonas aeruginosa

Project description:Pseudomonas aeruginosa is a major opportunistic human pathogen which employs a myriad of virulence factors. In people with cystic fibrosis (CF) P. aeruginosa frequently colonises the lungs and becomes a chronic infection that evolves to become less virulent over time, but often adapts to favour persistence in the host with alginate-producing mucoid, slow-growing, and antibiotic resistant phenotypes emerging. Cysteamine is an endogenous aminothiol which has been shown to prevent biofilm formation, reduce phenazine production, and potentiate antibiotic activity against P. aeruginosa, and has been investigated in clinical trials as an adjunct therapy for pulmonary exacerbations of CF. Here we demonstrate (for the first time in a prokaryote) that cysteamine prevents glycine utilisation by P. aeruginosa in common with reported activity blocking the glycine cleavage system in human cells. Despite the inhibition of glycine metabolism, cysteamine inhibits hydrogen cyanide (HCN) production by P. aeruginosa, implicating interference in the regulation of virulence. Cysteamine impaired chemotaxis and reductions in pyocyanin and exopolysaccharide production in cysteamine-treated P. aeruginosa and reduced toxicity of secreted factors in a Galleria mellonella model. Thus, cysteamine has additional potent anti-virulence properties targeting P. aeruginosa, further supporting its therapeutic potential in CF and other infections.

2021-08-19 | PXD027156 | Pride

Project description:Metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland

| PRJNA1044010 | ENA